Clinic effect of alendronate sodium treatment in osteoporosis patients with hip fracture.
- Author:
Gui-xing QIU
1
;
Zhi-hong WU
;
Jian-xiong SHEN
;
Xian-zheng LUO
;
Hai TANG
;
Yi-peng WANG
;
Xi-sheng WENG
;
Xin-yu YANG
;
Jin LIN
;
Jin JIN
;
Hong ZHAO
;
Ye TIAN
;
Jian-guo ZHANG
Author Information
- Publication Type:Clinical Trial
- MeSH: Absorptiometry, Photon; Aged; Alanine Transaminase; blood; Alendronate; pharmacology; therapeutic use; Bone Density; drug effects; Calcium; blood; Case-Control Studies; Double-Blind Method; Female; Hip Fractures; complications; Humans; Male; Middle Aged; Osteoporosis; blood; complications; drug therapy; Treatment Outcome
- From: Chinese Journal of Surgery 2004;42(6):347-350
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo assess efficacy and safety of alendronate sodium treatment in osteoporosis patients with hip fracture.
METHODSOne year randomized, double-blind clinical trial was carried out in 77 osteoporosis patients with hip fracture. The bone mineral density (BMD) in lumbar spine (L(2 - 4)), femoral neck (Neck), Wards triangle (Wards) and great trochanter (Troch) was measured by dual energy x-ray absorptiometer (DEXA).
RESULTSIn our study, alendronate sodium induced marked increases in BMD of the L(2 - 4) (7.0% +/- 13.0%), Neck (7.3% +/- 11.1%), Wards (4.6% +/- 5.9%), Troch (4.5% +/- 3.2%) (mean +/- s) versus decreases of 2.0% +/- 4.5%, -0.9% +/- 6.9%, 3.6% +/- 4.9% and 1.14% +/- 6.0% with placebo (P < 0.05). Blood Ca, P, ALP, BGP and Urine Pyd/C were no significant difference between before and after therapy. There were usually mild and transient side-effect, such as gastrointestinal symptoms.
CONCLUSIONAlendronate is an efficacy and safety drug in treatment of osteoporosis.
